#ASCO22: Following back-to-back TIGIT bombs, Roche offers insight into first PhIII trial fail
Roche’s Genentech suffered two consecutive Phase III fails for tiragolumab, the earliest in a series of anti-TIGIT drugs from Big Pharmas hoping to usher in the next generation of immune checkpoint therapies.
Today, the Swiss pharma unveiled specific data on SKYSCRAPER-02, the first trial that flopped, which tested tiragolumab alongside Tecentriq and chemotherapy as a first line of treatment in patients with extensive stage small cell lung cancer. Compared to an average overall survival of 12.9 months with only Tecentriq and chemotherapy, the addition of tiragolumab failed to move the needle at all, with an overall survival of 13.1 months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.